Indevus To Market Nebido In The U.S. Upon Approval

Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet